Iver Petersen and Dr

Iver Petersen and Dr. S100A14 binds directly to HER2 by co-immunoprecipitation and pull-down assays. Further study shows that residues 9561154 Leuprolide Acetate of the HER2 intracellular domain name and residue 83 of S100A14 are essential for the two proteins binding. Moreover, we observe a decrease of HER2 phosphorylation, downstream signaling, and HER2-stimulated cell proliferation in S100A14-silenced MCF-7, BT474, and SK-BR3 cells. Our findings suggest that S100A14 functions as a modulator of HER2 signaling and provide mechanistic evidence for its role in breast malignancy progression. == Introduction == HER2 (human epidermal growth factor receptor 2), also known as Neu, ErbB2, or p185, is usually a transmembrane protein that is encoded by theERBB2gene in humans. It belongs to the epidermal growth factor receptor (EGFR3/ErbB) family, which contains four family members: EGFR (HER1, ErbB1), HER2 (ErbB2, HER2/neu), HER3 (ErbB3), and HER4 (ErbB4). The EGFR family is usually involved in regulating cell proliferation, survival, and differentiation through interlinked signal transduction involving hyperactivation of the PI3K/AKT and MAPK/ERK pathways (1). Amplification or overexpression of theHER2gene occurs in 2025% of breast cancers and is associated with more aggressive disease and a worse outcome (2). HER2 is usually a typical receptor tyrosine kinase, comprising an extracellular domain name (ECD), a single transmembrane region, and an intracellular domain name (ICD) (3). HER2 is unique among the ErbB receptors Mouse monoclonal to EphB6 in that it does not bind a ligand directly but is usually preferentially recruited as a binding partner into heterodimers (4). S100 is usually a family of low molecular weight proteins that contains more than 20 family members and comprises the largest subfamily of EF-hand Ca2+-binding proteins (5). S100 proteins are composed of two EF-hand calcium-binding domains: the N-terminal domain name (also known as the S100 hand) and the C-terminal domain name (also known as the canonical EF-hand) (6). S100 proteins interact with several targets, such as RAGE, p53, CacyBP/BP, Jab-1, and matrix metalloproteinases, and regulate Ca2+homeostasis, protein phosphorylation, and degradation, thereby affecting cell proliferation and metastasis and many other biological events (5,7). S100A14 is usually a recently identified member of the S100 protein family. Differential expression of S100A14 has been reported in a variety of cell types and is overexpressed in certain types of tumors, such as lung, breast, and uterus, but underexpressed in some other tumors like colon, kidney, and rectal tumors (8). The heterogenic expression of S100A14 Leuprolide Acetate may indicate different and potentially tissue-specific functions. Down-regulated S100A14 expression was correlated with poor differentiation and simultaneous S100A14 underexpression, and S100A4 Leuprolide Acetate overexpression was correlated with Leuprolide Acetate high colorectal cancer metastatic potential (9). S100A14 was identified as a potential novel marker of breast cancer cells capable of predicting distant metastasis (10) and was found to be useful for detection and characterization of circulating tumor cells in peripheral blood from patients with colorectal, prostate, and breast cancers (11). Moreover, S100A14 was significantly associated with clinical outcome of breast malignancy patients. Our previous studies showed that S100A14 requires functional p53 to affectMMP2transcription (12). We also found that S100A14 could be secreted from stably overexpressing S100A14 of EC9706 cells, and low doses of extracellular S100A14 stimulate cell proliferation and promote survival in KYSE180 cells, but a high dose of S100A14 causes apoptosis via the mitochondrial pathway (13). We have previously shown that S100A14 is usually a new target for p53 and could affect p53 transactivity and stability, and S100A14 affects cell invasiveness by regulating MMP2 transcription in a p53-dependent manner (12). In the present study, we demonstrate for the first time that there is a strong correlation between S100A14 and HER2 expression in breast malignancy tissues, and S100A14 can interact with HER2 by co-immunoprecipitation and pull-down assays. Further study revealed that residues 9561154 of the HER2 intracellular domain name and residue 83 of S100A14 are essential for the two proteins binding. Furthermore, we found that S100A14 plays an important role in the HER2-induced cell proliferation of MCF-7, BT474,.